Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy

Adv Sci (Weinh). 2023 Dec;10(36):e2307935. doi: 10.1002/advs.202307935.
No abstract available

Publication types

  • Published Erratum